STOCK TITAN
  1. Home
  2. Sec-filings
  3. HCA
  4. [8-K] HCA Healthcare, Inc. Reports Material Event

HCA Healthcare (NYSE: HCA) Chief Clinical Officer plans leadership transition

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

HCA Healthcare, Inc. announced that Dr. Michael Cuffe, its Executive Vice President and Chief Clinical Officer, will step down from his role effective August 31, 2026.

He will remain with the company in a transitional role until February 2027 and will be eligible for benefits under HCA Healthcare’s executive severance policy and applicable incentive plans.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Step-down effective date August 31, 2026 End of role as Executive Vice President and Chief Clinical Officer
Transition period end February 2027 End of Dr. Cuffe’s transitional role with HCA Healthcare
Telephone number (615) 344-9551 Registrant’s telephone number for HCA Healthcare’s principal executive offices
Executive Vice President financial
"Dr. Cuffe will step down as Executive Vice President and Chief Clinical Officer"
An executive vice president is a high-ranking leader within a company who oversees major parts of its operations or strategies. Think of them as senior managers responsible for important areas, similar to a vice principal in a school hierarchy. Their role matters to investors because they help guide the company's success and decision-making at the top level.
Chief Clinical Officer financial
"step down as Executive Vice President and Chief Clinical Officer effective August 31, 2026"
executive severance policy financial
"eligible to receive benefits according to the Company’s executive severance policy and applicable incentive plans"
emerging growth company regulatory
"Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0000860730 0000860730 2026-06-15 2026-06-15
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 18, 2026 (June 15, 2026)

 

 

HCA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-11239   27-3865930

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

One Park Plaza, Nashville, Tennessee   37203
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (615) 344-9551

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $.01 par value per share   HCA   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 15, 2026, Dr. Michael Cuffe and HCA Healthcare, Inc. (the “Company”) agreed that Dr. Cuffe will step down as Executive Vice President and Chief Clinical Officer effective August 31, 2026, and thereafter continue in a transitional role with the Company until February 2027. Dr. Cuffe will be eligible to receive benefits according to the Company’s executive severance policy and applicable incentive plans.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

HCA HEALTHCARE, INC.
By:  

/s/ John M. Franck II

  John M. Franck II
  Vice President – Legal and Corporate Secretary

Date: June 18, 2026

Source: View Original Filing on SEC EDGAR

FAQ

What leadership change did HCA (HCA) disclose in this 8-K?

HCA Healthcare disclosed that Dr. Michael Cuffe will step down as Executive Vice President and Chief Clinical Officer on August 31, 2026. He will then serve in a transitional role until February 2027, supporting continuity in clinical leadership during the change.

When will HCA (HCA) Chief Clinical Officer Michael Cuffe leave his role?

Dr. Michael Cuffe will leave his role as Executive Vice President and Chief Clinical Officer effective August 31, 2026. After that date, he will continue with HCA Healthcare in a transitional capacity through February 2027 before fully departing the company.

Will Dr. Michael Cuffe receive severance benefits from HCA (HCA)?

Yes. Dr. Michael Cuffe will be eligible for benefits under HCA Healthcare’s executive severance policy and applicable incentive plans. The filing does not detail specific amounts, but confirms he qualifies according to existing company policies governing executive departures.

What role will Dr. Michael Cuffe have at HCA (HCA) after August 31, 2026?

After August 31, 2026, Dr. Michael Cuffe will continue in a transitional role with HCA Healthcare until February 2027. This transitional position is intended to support an orderly handoff of his responsibilities as Executive Vice President and Chief Clinical Officer.

Does the HCA (HCA) filing mention changes to its business operations?

The filing focuses on the leadership transition of Dr. Michael Cuffe and does not describe specific operational changes. It notes his end date as Chief Clinical Officer and subsequent transitional role, along with eligibility for severance and incentive-related benefits.

Filing Exhibits & Attachments

3 documents

Other Documents